Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016

  • ID: 3691122
  • Company Profile
  • 122 pages
  • Global Markets Direct
1 of 4
Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016

Summary

‘Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Otsuka Holdings Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Otsuka Holdings Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Otsuka Holdings Co., Ltd.
- The report provides overview of Otsuka Holdings Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Otsuka Holdings Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Otsuka Holdings Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Otsuka Holdings Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Otsuka Holdings Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Otsuka Holdings Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Otsuka Holdings Co., Ltd. Snapshot

Otsuka Holdings Co., Ltd. Overview

Key Information

Key Facts

Otsuka Holdings Co., Ltd. - Research and Development Overview

Key Therapeutic Areas

Otsuka Holdings Co., Ltd. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Otsuka Holdings Co., Ltd. - Pipeline Products Glance

Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Otsuka Holdings Co., Ltd. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Otsuka Holdings Co., Ltd. - Drug Profiles

(carteolol hydrochloride + latanoprost)

Product Description

Mechanism of Action

R&D Progress

(tipiracil hydrochloride + trifluridine)

Product Description

Mechanism of Action

R&D Progress

levetiracetam

Product Description

Mechanism of Action

R&D Progress

ponatinib hydrochloride

Product Description

Mechanism of Action

R&D Progress

tolvaptan

Product Description

Mechanism of Action

R&D Progress

(aripiprazole + sertraline)

Product Description

Mechanism of Action

R&D Progress

(gimeracil + oteracil + tegafur)

Product Description

Mechanism of Action

R&D Progress

aripiprazole ER

Product Description

Mechanism of Action

R&D Progress

AVP-786

Product Description

Mechanism of Action

R&D Progress

brexpiprazole

Product Description

Mechanism of Action

R&D Progress

delamanid

Product Description

Mechanism of Action

R&D Progress

nabiximols

Product Description

Mechanism of Action

R&D Progress

rebamipide

Product Description

Mechanism of Action

R&D Progress

(dextromethorphan + quinidine sulfate)

Product Description

Mechanism of Action

R&D Progress

OCV-501

Product Description

Mechanism of Action

R&D Progress

OPA-15406

Product Description

Mechanism of Action

R&D Progress

OPS-2071

Product Description

Mechanism of Action

R&D Progress

probucol

Product Description

Mechanism of Action

R&D Progress

tetomilast

Product Description

Mechanism of Action

R&D Progress

OPA-6566

Product Description

Mechanism of Action

R&D Progress

OPB-111001

Product Description

Mechanism of Action

R&D Progress

LPC-01

Product Description

Mechanism of Action

R&D Progress

LUAF-20513

Product Description

Mechanism of Action

R&D Progress

OCVC-02

Product Description

Mechanism of Action

R&D Progress

OPB-111077

Product Description

Mechanism of Action

R&D Progress

OPC-108459

Product Description

Mechanism of Action

R&D Progress

OPC-39436

Product Description

Mechanism of Action

R&D Progress

OPC-64005

Product Description

Mechanism of Action

R&D Progress

OPC-28326

Product Description

Mechanism of Action

R&D Progress

Otsuka Holdings Co., Ltd. - Pipeline Analysis

Otsuka Holdings Co., Ltd. - Pipeline Products by Target

Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration

Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type

Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action

Otsuka Holdings Co., Ltd. - Recent Pipeline Updates

Otsuka Holdings Co., Ltd. - Dormant Projects

Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

(gimeracil + oteracil + tegafur)

(tipiracil hydrochloride + trifluridine)

AVP-13358

AZD-2479

brexpiprazole

dasatinib

OCV-101

OPB-31121

OPB-51602

rebamipide

Otsuka Holdings Co., Ltd. - Company Statement

Otsuka Holdings Co., Ltd. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Otsuka Holdings Co., Ltd., Key Information

Otsuka Holdings Co., Ltd., Key Facts

Otsuka Holdings Co., Ltd. - Pipeline by Indication, 2016

Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2016

Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2016

Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016

Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2016

Otsuka Holdings Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016

Otsuka Holdings Co., Ltd. - Pre-Registration, 2016

Otsuka Holdings Co., Ltd. - Phase III, 2016

Otsuka Holdings Co., Ltd. - Phase II, 2016

Otsuka Holdings Co., Ltd. - Phase I, 2016

Otsuka Holdings Co., Ltd. - Preclinical, 2016

Otsuka Holdings Co., Ltd. - Pipeline by Target, 2016

Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2016

Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2016

Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action, 2016

Otsuka Holdings Co., Ltd. - Recent Pipeline Updates, 2016

Otsuka Holdings Co., Ltd. - Dormant Developmental Projects,2016

Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products, 2016

Otsuka Holdings Co., Ltd., Other Locations

Otsuka Holdings Co., Ltd., Subsidiaries

List of Figures

Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Indication, 2016

Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2016

Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2016

Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016

Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2016

Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Target, 2016

Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2016

Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2016

Otsuka Holdings Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll